Popular topics to explore
India’s Biopharma Push Could Create the Next Wave of Healthcare Growth
India is rapidly strengthening its position in the global biopharmaceutical industry through increased focus on innovation, manufacturing, clinical research, and regulatory development. At the 2nd Pharma Summit & Awards 2026, policymakers h…
Why Gujarat Themis Biosyn Rose 4% What a ₹1,300 Crore Japanese Acquisition Tells Investors
Gujarat Themis Biosyn shares rose 4% to ₹383.65 after announcing the acquisition of 100% stake in MicroBiopharm Japan a Japanese pharma and specialty chemicals company with over six decades of fermentation expertise for ₹1,300 crore (JPY 21…
Gujarat Themis Biosyn Makes ₹1,300 Crore Global Bet to Strengthen Biotech and CDMO Capabilities
Gujarat Themis Biosyn Ltd (GUJTHEM) the has announced a major international expansion move by signing a definitive agreement to acquire 100% equity of Japan-based MicroBiopharm Japan Co., Ltd. (MBJ) through its wholly owned subsidiary, The…
Gujarat Themis Biosyn Ltd (GUJTHEM
GUJTHEM
Strengths
Niche Pharma Manufacturer: Focused on APIs and pharmaceutical intermediates.
Strategic Location: Manufacturing facility in Gujarat, a major pharma hub.
Regulatory Approvals: Compliance with domestic and international…
